Gilead Sciences Company Profile (NASDAQ:GILD)

About Gilead Sciences (NASDAQ:GILD)

Gilead Sciences logoGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:GILD
  • CUSIP: 37555810
  • Web: www.gilead.com
Capitalization:
  • Market Cap: $107.92173 billion
  • Outstanding Shares: 1,305,926,000
Average Prices:
  • 50 Day Moving Avg: $77.54
  • 200 Day Moving Avg: $70.38
  • 52 Week Range: $63.76 - $86.27
P/E:
  • Trailing P/E Ratio: 8.98
  • Foreward P/E Ratio: 11.62
  • P/E Growth: -1.14
Sales & Book Value:
  • Annual Revenue: $28.47 billion
  • Price / Sales: 3.79
  • Book Value: $17.36 per share
  • Price / Book: 4.76
Dividend:
  • Annual Dividend: $2.08
  • Dividend Yield: 2.5%
Profitability:
  • EBIDTA: $17.97 billion
  • Net Margins: 42.90%
  • Return on Equity: 66.07%
  • Return on Assets: 23.03%
Debt:
  • Debt-to-Equity Ratio: 1.16%
  • Current Ratio: 3.37%
  • Quick Ratio: 3.20%
Misc:
  • Average Volume: 10.17 million shs.
  • Beta: 1.19
  • Short Ratio: 2.17
 

Frequently Asked Questions for Gilead Sciences (NASDAQ:GILD)

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Wednesday, July 26th. Investors of record on Friday, September 15th will be paid a dividend of $0.52 per share on Thursday, September 28th. This represents a $2.08 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date of this dividend is Thursday, September 14th. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings data on Wednesday, July, 26th. The company reported $2.56 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business's revenue was down 8.2% on a year-over-year basis. During the same quarter last year, the business earned $3.08 EPS. View Gilead Sciences' Earnings History.

When will Gilead Sciences make its next earnings announcement?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for Gilead Sciences.

Where is Gilead Sciences' stock going? Where will Gilead Sciences' stock price be in 2017?

26 brokerages have issued 1-year price objectives for Gilead Sciences' shares. Their predictions range from $68.00 to $100.00. On average, they expect Gilead Sciences' stock price to reach $84.62 in the next year. View Analyst Ratings for Gilead Sciences.

What are analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:

  • 1. According to Zacks Investment Research, "Gilead is all set to acquire Kite Pharma and enter the CAR T therapy space which represents immense potential at this juncture and a potential approval of lead candidate axi-cell will be a significant boost for Gilead’s prospects which has dampened of late. We note that an acquisition announcement was on the cards as Gilead had a strong cash balance and the decline in the once lucrative hepatitis C (HCV) market due to competitive pressure made the company look for strategic alternatives.  Gilead is known for its presence in the HCV market because of its blockbuster HCV drugs, Sovaldi and Harvoni. However, the HCV franchise is under pressure because of competition and pricing issues. Meanwhile, the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens in the U.S. and EU. Shares of the company have outperformed the industry so far in 2017." (9/11/2017)
  • 2. Maxim Group analysts commented, "Gilead reported 1Q17 results with total revenues of $6.5B, which just missed consensus expectations. Total revenues declined by 11% compared to the prior quarter’s revenues of $7.2B, and product sales were $6.4B, representing a 12% decrease sequentially. HCV product reveneues fell to $2.6B vs. $3.2B in 4Q16, down 20% as a result of declining revenues for Harvoni ($1.4B), Sovaldi ($313M), and Epclusa ($892M)." (5/3/2017)
  • 3. Jefferies Group LLC analysts commented, "U.S. sales of Harvoni are tracking in line for 1Q and Epclusa ahead of cons., which should help GILD hit numbers for now and perhaps improve sentiment. We are cautious about overinterpreting recent Rx trends given VA/pricing dynamics are not captured and many headwinds could increase over '17, and remain below cons. for out-yrs. Still, we like GILD on LT HIV sustainability and BD optionality, and believe any deal & acceptable HCV 1Q #s could improve sentiment." (3/15/2017)

Who are some of Gilead Sciences' key competitors?

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:

  • John C. Martin Ph.D., Executive Chairman of the Board
  • John F. Milligan Ph.D., Chief Executive Officer, Director
  • Robin L. Washington, Chief Financial Officer, Executive Vice President
  • Kevin B. Young, Chief Operating Officer
  • Norbert W. Bischofberger Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
  • Gregg H. Alton, Executive Vice President - Corporate and Medical Affairs
  • James R. Meyers, Executive Vice President - Worldwide Commercial Operations
  • John F. Cogan Jr. Ph.D., Lead Independent Director
  • Kelly A. Kramer, Independent Director
  • Kevin E. Lofton, Independent Director

Who owns Gilead Sciences stock?

Gilead Sciences' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.03%), Vanguard Group Inc. (7.11%), State Street Corp (4.45%), Bank of New York Mellon Corp (2.36%), FMR LLC (1.76%) and Capital Research Global Investors (1.40%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Norbert W Bischofberger, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Who sold Gilead Sciences stock? Who is selling Gilead Sciences stock?

Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Capital Research Global Investors, Los Angeles Capital Management & Equity Research Inc., State Street Corp, American Century Companies Inc., AJO LP, Thrivent Financial For Lutherans and Nordea Investment Management AB. Company insiders that have sold Gilead Sciences stock in the last year include Gregg H Alton, James R Meyers, John C Martin, John Francis Cogan, John W Madigan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.

Who bought Gilead Sciences stock? Who is buying Gilead Sciences stock?

Gilead Sciences' stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., The Manufacturers Life Insurance Company , BlackRock Inc., Pioneer Investment Management Inc., Janus Henderson Group PLC, Neuberger Berman Group LLC and Harbour Capital Advisors LLC. View Insider Buying and Selling for Gilead Sciences.

How do I buy Gilead Sciences stock?

Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of Gilead Sciences stock can currently be purchased for approximately $82.63.


MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)
Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  1,582 (Vote Outperform)
Underperform Votes:  556 (Vote Underperform)
Total Votes:  2,138
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Gilead Sciences (NASDAQ:GILD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 9 Hold Ratings, 17 Buy Ratings
Consensus Rating:Buy (Score: 2.65)
Consensus Price Target: $84.62 (2.40% upside)

Analysts' Ratings History for Gilead Sciences (NASDAQ:GILD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/20/2017Leerink SwannReiterated RatingMarket Perform$82.00 -> $87.00MediumView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageOutperform -> Outperform$94.00LowView Rating Details
9/6/2017Berenberg BankReiterated RatingBuy$86.00 -> $96.00LowView Rating Details
9/6/2017Wells Fargo & CompanyBoost Price TargetMarket Perform$73.00 -> $81.00LowView Rating Details
8/31/2017Cowen and CompanyReiterated RatingOutperform$90.00MediumView Rating Details
8/31/2017Deutsche Bank AGReiterated RatingBuy$81.00MediumView Rating Details
8/31/2017William BlairReiterated RatingOutperform -> Outperform$87.00LowView Rating Details
8/31/2017ArgusUpgradeHold -> Buy$100.00HighView Rating Details
8/28/2017Needham & Company LLCReiterated RatingHoldLowView Rating Details
8/29/2017Robert W. BairdReiterated RatingOutperform$87.00LowView Rating Details
8/29/2017Credit Suisse GroupReiterated RatingOutperform$79.00 -> $85.00MediumView Rating Details
8/28/2017Maxim GroupReiterated RatingHoldHighView Rating Details
7/27/2017BMO Capital MarketsReiterated RatingOutperform$72.00 -> $82.00MediumView Rating Details
7/27/2017Jefferies Group LLCReiterated RatingHold$83.00MediumView Rating Details
7/27/2017J P Morgan Chase & CoSet Price TargetOverweight$80.00 -> $85.00MediumView Rating Details
7/26/2017Redburn PartnersInitiated CoverageBuyMediumView Rating Details
7/11/2017Morgan StanleyReiterated RatingEqual WeightLowView Rating Details
5/3/2017GabelliReiterated RatingBuy$85.00MediumView Rating Details
5/3/2017Barclays PLCReiterated RatingOverweight$85.00MediumView Rating Details
5/3/2017Stifel NicolausReiterated RatingBuy$87.00MediumView Rating Details
4/21/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
3/13/2017Bank of America CorporationReiterated RatingNeutral$76.00 -> $68.19LowView Rating Details
3/13/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$70.00 -> $68.00LowView Rating Details
3/1/2017MizuhoLower Price TargetBuy$88.00 -> $77.00N/AView Rating Details
2/8/2017Citigroup Inc.DowngradeBuy -> Neutral$87.00 -> $76.00N/AView Rating Details
10/15/2016Evercore ISISet Price TargetBuy$90.00N/AView Rating Details
7/27/2016S&P Equity ResearchReiterated RatingStrong-BuyN/AView Rating Details
5/4/2016Oppenheimer Holdings, Inc.Reiterated RatingBuy$120.00 -> $116.00N/AView Rating Details
2/3/2016Standpoint ResearchInitiated CoverageBuy$110.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$111.00N/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Gilead Sciences (NASDAQ:GILD)
Earnings by Quarter for Gilead Sciences (NASDAQ:GILD)
Earnings History by Quarter for Gilead Sciences (NASDAQ GILD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017$2.11N/AView Earnings Details
7/26/2017Q2 2017$2.11$2.56$6.35 billion$7.14 billionViewN/AView Earnings Details
5/2/2017Q1 2017$2.18$2.20$6.66 billion$6.51 billionViewListenView Earnings Details
2/7/2017Q416$2.61$2.70$7.16 billion$7.30 billionViewListenView Earnings Details
11/1/2016Q316$2.87$2.75$7.47 billion$7.40 billionViewListenView Earnings Details
7/25/2016Q216$3.02$3.08$7.80 billion$7.78 billionViewListenView Earnings Details
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details
7/28/2015Q215$2.83$3.15$7.60 billion$8.22 billionViewListenView Earnings Details
4/30/2015Q115$2.78$2.94$6.81 billion$7.59 billionViewListenView Earnings Details
2/3/2015Q414$2.27$2.43$6.68 million$7.31 billionViewListenView Earnings Details
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details
7/23/2014Q214$1.61$2.36$5.68 billion$6.53 billionViewListenView Earnings Details
4/22/2014Q114$0.75$1.48$3.80 billion$5.00 billionViewListenView Earnings Details
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details
10/29/2013Q313$0.48$0.52$2.72 billion$2.78 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details
5/2/2013Q1 2013$0.50$0.48$2.57 billion$2.53 billionViewListenView Earnings Details
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.59 billionViewListenView Earnings Details
10/23/2012$0.94$1.00ViewN/AView Earnings Details
7/26/2012$0.95$0.99ViewN/AView Earnings Details
4/26/2012$0.94$0.91ViewN/AView Earnings Details
2/2/2012$1.04$0.97ViewN/AView Earnings Details
10/27/2011$1.01$1.02ViewN/AView Earnings Details
4/20/2011$0.97$0.87ViewN/AView Earnings Details
1/25/2011$0.95$0.95ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Gilead Sciences (NASDAQ:GILD)
2017 EPS Consensus Estimate: $8.25
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$2.09$2.42$2.23
Q2 20173$2.01$2.29$2.15
Q3 20173$1.88$2.26$2.01
Q4 20173$1.76$2.03$1.86
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Gilead Sciences (NASDAQ:GILD)
Next Dividend:9/28/2017
Annual Dividend:$2.08
Dividend Yield:2.52%
Payout Ratio:22.58% (Trailing 12 Months of Earnings)
24.24% (Based on This Year's Estimates)
29.25% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Gilead Sciences (NASDAQ:GILD)

Dividend History by Quarter for Gilead Sciences (NASDAQ GILD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/26/2017quarterly$0.522.78%9/14/20179/15/20179/28/2017
5/2/2017quarterly$0.523.09%6/14/20176/16/20176/29/2017
2/7/2017quarterly$0.523.11%3/14/20173/16/20173/30/2017
11/1/2016quarterly$0.472.59%12/13/201612/15/201612/29/2016
7/25/2016quarterly$0.472.32%9/14/20169/16/20169/29/2016
4/28/2016quarterly$0.472.13%6/14/20166/16/20166/29/2016
2/2/2016quarterly$0.431.99%3/14/20163/16/20163/30/2016
10/27/2015quarterly$0.431.59%12/14/201512/16/201512/30/2015
7/28/2015quarterly$0.431.49%9/14/20159/16/20159/29/2015
4/30/2015quarterly$0.436/12/20156/16/20156/29/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Gilead Sciences (NASDAQ:GILD)
Insider Ownership Percentage: 1.30%
Institutional Ownership Percentage: 73.97%
Insider Trades by Quarter for Gilead Sciences (NASDAQ:GILD)
Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)
Insider Trades by Quarter for Gilead Sciences (NASDAQ:GILD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/7/2017Robin L WashingtonCFOSell51,820$85.00$4,404,700.00View SEC Filing  
9/1/2017Gregg H AltonEVPSell25,000$83.05$2,076,250.00View SEC Filing  
9/1/2017John C MartinInsiderSell73,333$83.11$6,094,705.63View SEC Filing  
8/31/2017James R MeyersEVPSell60,000$83.19$4,991,400.00View SEC Filing  
8/30/2017Gregg H AltonEVPSell50,000$79.00$3,950,000.00View SEC Filing  
8/1/2017Gregg H AltonEVPSell15,000$75.88$1,138,200.00View SEC Filing  
8/1/2017John C MartinInsiderSell73,333$75.86$5,563,041.38View SEC Filing  
7/21/2017Gregg H AltonEVPSell40,000$74.00$2,960,000.00View SEC Filing  
7/3/2017Gregg H AltonEVPSell5,000$71.06$355,300.00View SEC Filing  
7/3/2017John C MartinInsiderSell73,333$71.00$5,206,643.00View SEC Filing  
5/9/2017John Francis CoganDirectorSell9,943$67.25$668,666.75View SEC Filing  
4/3/2017John C MartinInsiderSell73,333$67.18$4,926,510.94View SEC Filing  
3/30/2017Gregg H AltonEVPSell5,000$67.48$337,400.00View SEC Filing  
1/3/2017John C MartinInsiderSell73,337$73.59$5,396,869.83View SEC Filing  
11/18/2016John W MadiganDirectorSell105,000$74.86$7,860,300.00View SEC Filing  
10/3/2016John C MartinInsiderSell100,000$77.63$7,763,000.00View SEC Filing  
9/22/2016Gregg H AltonEVPSell5,000$81.84$409,200.00View SEC Filing  
9/6/2016John F MilliganInsiderSell70,000$77.74$5,441,800.00View SEC Filing  
9/1/2016John C MartinInsiderSell100,000$77.48$7,748,000.00View SEC Filing  
8/24/2016Kevin E LoftonDirectorSell3,500$81.97$286,895.00View SEC Filing  
8/1/2016John C MartinInsiderSell100,000$80.50$8,050,000.00View SEC Filing  
8/1/2016Paul Rutherford CarterEVPSell2,000$79.81$159,620.00View SEC Filing  
7/5/2016John F MilliganCEOSell112,000$84.33$9,444,960.00View SEC Filing  
7/1/2016John C MartinChairmanSell100,000$84.73$8,473,000.00View SEC Filing  
7/1/2016Paul Rutherford CarterEVPSell2,000$83.12$166,240.00View SEC Filing  
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.00View SEC Filing  
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.00View SEC Filing  
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.00View SEC Filing  
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.00View SEC Filing  
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.00View SEC Filing  
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00View SEC Filing  
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.00View SEC Filing  
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.00View SEC Filing  
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.00View SEC Filing  
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00View SEC Filing  
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50View SEC Filing  
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.00View SEC Filing  
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.00View SEC Filing  
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.00View SEC Filing  
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.00View SEC Filing  
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00View SEC Filing  
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.00View SEC Filing  
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.00View SEC Filing  
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00View SEC Filing  
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.00View SEC Filing  
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00View SEC Filing  
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.00View SEC Filing  
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00View SEC Filing  
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.00View SEC Filing  
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.00View SEC Filing  
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.00View SEC Filing  
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.00View SEC Filing  
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00View SEC Filing  
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.21View SEC Filing  
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00View SEC Filing  
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.00View SEC Filing  
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00View SEC Filing  
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.50View SEC Filing  
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.00View SEC Filing  
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.00View SEC Filing  
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00View SEC Filing  
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.00View SEC Filing  
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.84View SEC Filing  
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00View SEC Filing  
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.50View SEC Filing  
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.00View SEC Filing  
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00View SEC Filing  
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.96View SEC Filing  
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.00View SEC Filing  
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.50View SEC Filing  
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00View SEC Filing  
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.00View SEC Filing  
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.00View SEC Filing  
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00View SEC Filing  
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.00View SEC Filing  
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.00View SEC Filing  
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.74View SEC Filing  
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.00View SEC Filing  
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Gilead Sciences (NASDAQ:GILD)
Latest Headlines for Gilead Sciences (NASDAQ:GILD)
Source:
DateHeadline
finance.yahoo.com logoShould Value Investors Consider Gilead Sciences (GILD) Stock? - Yahoo Finance
finance.yahoo.com - September 20 at 3:48 PM
seekingalpha.com logoWhy Gilead May Regain Growth Stock Status - Seeking Alpha
seekingalpha.com - September 20 at 3:48 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Earns Market Perform Rating from Leerink Swann
www.americanbankingnews.com - September 20 at 2:38 PM
finance.yahoo.com logoGilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors
finance.yahoo.com - September 19 at 7:03 PM
finance.yahoo.com logoTaking On Exposure to Innovative Biotechnology Stocks
finance.yahoo.com - September 19 at 7:03 PM
finance.yahoo.com logoShould Value Investors Consider Gilead Sciences (GILD) Stock?
finance.yahoo.com - September 19 at 7:03 PM
fool.com logoGilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors
www.fool.com - September 19 at 6:55 AM
finance.yahoo.com logoThe IBB Biotechnology ETF: The Drugs You Need?
finance.yahoo.com - September 18 at 6:36 PM
finance.yahoo.com logoBenefitting from IBB’s Lower Expense Ratio
finance.yahoo.com - September 18 at 6:36 PM
finance.yahoo.com logoAfter Gilead Sciences, More Biotech M&A?
finance.yahoo.com - September 15 at 7:41 PM
fool.com logo3 Reasons Why Gilead Sciences Stock Is a Buy Now
www.fool.com - September 15 at 8:16 AM
finance.yahoo.com logoIs It Premature to Celebrate Gilead Sciences, Inc.’s (GILD) Kite Pharma Momentum? Jefferies Looks Beyond the Recent Bull Rally
finance.yahoo.com - September 15 at 12:46 AM
seekingalpha.com logoGilead Sciences prices $3B in debt for Kite Pharma deal
seekingalpha.com - September 14 at 7:58 PM
finance.yahoo.com logoOptions Traders Expect Huge Moves in Gilead Sciences (GILD) Stock
finance.yahoo.com - September 14 at 7:43 PM
finance.yahoo.com logoGilead Sciences, Inc. -- Moody's assigns A3 to Gilead's new sr. notes; stable outlook
finance.yahoo.com - September 14 at 7:43 PM
finance.yahoo.com logoETFs with exposure to Gilead Sciences, Inc. : September 14, 2017
finance.yahoo.com - September 14 at 7:43 PM
finance.yahoo.com logoGilead Prices $3 Billion of Senior Unsecured Notes
finance.yahoo.com - September 14 at 7:43 PM
americanbankingnews.com logoRoyal Bank Of Canada Begins Coverage on Gilead Sciences, Inc. (GILD)
www.americanbankingnews.com - September 14 at 5:26 PM
finance.yahoo.com logoMust-Know Recent Developments for Gilead
finance.yahoo.com - September 14 at 1:59 AM
finance.yahoo.com logoGilead: Too Early for Kite Credit?
finance.yahoo.com - September 14 at 1:59 AM
finance.yahoo.com logoGilead Sciences, Inc. :GILD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
finance.yahoo.com - September 14 at 1:59 AM
finance.yahoo.com logoGilead Sciences, Inc.'s Best Investment of 2017 (Hint: It Wasn't Kite Pharmaceuticals)
finance.yahoo.com - September 14 at 1:59 AM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Downgraded by ValuEngine
www.americanbankingnews.com - September 14 at 12:56 AM
fool.com logoGilead Sciences, Inc.'s Best Investment of 2017 (Hint: It Wasn't Kite Pharmaceuticals)
www.fool.com - September 13 at 3:59 PM
nasdaq.com logoEx-Dividend Reminder: Gilead Sciences, Hill-Rom Holdings and Owens & Minor
www.nasdaq.com - September 12 at 7:54 PM
finance.yahoo.com logoHow Gilead’s HCV Drugs Portfolio Performed in 2Q17
finance.yahoo.com - September 12 at 7:54 PM
finance.yahoo.com logoHow Did Gilead’s Blockbuster Drug Harvoni Perform in 2Q17?
finance.yahoo.com - September 12 at 7:54 PM
finance.yahoo.com logoHow Gilead’s Other Products Performed in 2Q17
finance.yahoo.com - September 12 at 7:54 PM
fool.com logo3 Stocks for Future Millionaires
www.fool.com - September 12 at 8:18 AM
finance.yahoo.com logoCowen Shares Key Insights on Gilead Sciences, Inc. (GILD) Following Management Meetings
finance.yahoo.com - September 12 at 12:35 AM
finance.yahoo.com logoHow Did Gilead’s Revenue Trend in 2Q17?
finance.yahoo.com - September 12 at 12:35 AM
finance.yahoo.com logoHow Gilead’s HIV and HBV Portfolios Performed in 2Q17
finance.yahoo.com - September 12 at 12:35 AM
americanbankingnews.com logoInsider Selling: Gilead Sciences, Inc. (GILD) CFO Sells 51,820 Shares of Stock
www.americanbankingnews.com - September 11 at 10:20 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Upgraded to "B-" by TheStreet
www.americanbankingnews.com - September 11 at 7:02 PM
fool.com logo5 Tough Questions for Gilead Sciences About the Kite Pharma Acquisition
www.fool.com - September 11 at 4:17 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - September 11 at 10:10 AM
americanbankingnews.com logoHead to Head Comparison: Gilead Sciences (GILD) and Vascular Biogenics (VBLT)
www.americanbankingnews.com - September 10 at 8:52 AM
nasdaq.com logoGILD Crosses Above Average Analyst Target - Nasdaq
www.nasdaq.com - September 9 at 11:37 PM
finance.yahoo.com logoUpgrade Confirms Gilead's Price Strength
finance.yahoo.com - September 8 at 7:34 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Upgraded to "Strong-Buy" at ValuEngine
www.americanbankingnews.com - September 8 at 12:36 AM
finance.yahoo.com logoAlternative Perspectives On The Biotech M&A Environment
finance.yahoo.com - September 7 at 7:16 PM
finance.yahoo.com logoThe Trump White House Gave These Mutual Funds a Big Boost
finance.yahoo.com - September 7 at 7:16 PM
finance.yahoo.com logoUnusual activity in a biotech and a travel stock
finance.yahoo.com - September 7 at 7:16 PM
finance.yahoo.com logoAre These Healthcare Stocks Top Takeover Targets?
finance.yahoo.com - September 7 at 7:16 PM
finance.yahoo.com logoDespite biotech's epic run, these names are still a barga...
finance.yahoo.com - September 7 at 7:16 PM
finance.yahoo.com logoMyth Busting: Trump Trade A Fallacy
finance.yahoo.com - September 7 at 7:16 PM
fool.com logoAre You Buying Gilead Sciences, Inc. for the Wrong Reason?
www.fool.com - September 7 at 3:30 PM
fool.com logo5 Things Gilead Sciences' Management Just Said That You'll Want to Know
www.fool.com - September 7 at 6:28 AM
americanbankingnews.com logoJohn C. Martin Sells 73,333 Shares of Gilead Sciences, Inc. (GILD) Stock
www.americanbankingnews.com - September 6 at 10:28 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) EVP Gregg H. Alton Sells 25,000 Shares
www.americanbankingnews.com - September 6 at 7:40 PM

Social

Chart

Gilead Sciences (GILD) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff